Nucleophosmin (NPM) is frequently overexpressed in leukemias and other tumors.
Introduction
Nucleophosmin (NPM) is a multi-functional protein that plays important roles in the regulation of cell proliferation and apoptosis (1) . The level of NPM is frequently found to be significantly higher in tumor and proliferating cells than in resting cells (2) (3) (4) (5) (6) .
Normal cells induce genetically encoded programs that prevent deregulated proliferation and thus protect multicellular organisms from cancer progression. Two such programs are apoptosis and senescence that are normally triggered by DNA damage or other stresses. Our recent studies demonstrated that overexpression of NPM suppresses oncogene-induced senescence and apoptosis and accelerated transformation in cells deficient for the Fanconi complementation group C (Fancc) gene and the ataxia telangiectasia mutated (Atm) gene (7). Therefore, NPM could be a potential therapeutic target for neoplastic diseases.
There is increasing interest in employing peptides and proteins as therapeutic compounds for human cancers. For example, several peptides derived from tumor suppressors as well as oncogenes have been developed as anti-tumorigenic cargoes and proved to be effective in inhibition of tumor cell growth (8-10). Although peptide-based compounds have limitations owing to poor permeability and low selectivity, recent studies have demonstrated that large cargoes, proteins, and peptides can be delivered intracellularly if conjugated to the protein transduction domain (PTD) derived from the HIV-1 TAT protein (11, 12). Indeed, rapid and receptor-independent uptake of TAT-conjugated peptides has been demonstrated to occur in many cell types and animals (13) (14) (15) .
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In this study, we generated a NPM-derived peptide fused to TAT (TAT-NPM∆C) and demonstrated in an inflammation-associated leukemic mouse model that TAT induced rapid and efficient delivery of the peptide into leukemic cells. TAT-NPM∆C caused growth inhibition and apoptosis of leukemic cells, and significantly delayed leukemic development in mice. TAT-NPM∆C associated with endogenous NPM proteins, formed complexes with endogenous NPM and the NF-κB subunit p65, and abrogated NF-κB transactivation at promoters of several important antiapoptotic and inflammatory genes controlled by NF-κB in leukemic cells. Thus, the results suggest that the TAT-delivered NPM mutant may provide a novel therapy for tumors that require NF-κB signaling for survival.
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Materials and Methods
Cloning, expression, and purification of TAT-NPM fusion proteins. The fulllength human NPM (GeneBank sequence accession number BC009623) and its Nterminally (NPM∆N) and C-terminally (NPM∆C) deleted cDNAs were amplified by polymerase chain reaction, using Pfu DNA polymerase (Stratagene) and the following primer pairs: 5'-CGGGATCCGGAAGATTCGATGGACATG/5'-CCGCT CGAGAAGAGACTTCCTCCACTG, 5'-CGGGATCCGGAAGAAAAAGCGCCAGTG /5'-CCGCTCGAGAAGAGACTTCCTCCACTG and 5'-CGGGATCCGGAAGATTC GATGGACATG/5'-CCGCTCGAGTTCATCATCATCCTCTTCA, respectively. The resulting PCR fragments were subcloned into the BamH1 and Xho1 sites of the pTAT-2.1 vector (kindly provided by Steven F Dowdy, University of California School of Medicine, San Diego, CA) to create pTAT-NPM, pTAT-NPM∆N, and pTAT-NPM∆C, respectively. The TAT-NPM fusion proteins were expressed in E. coli strain BL21 (DE3; Novagen). Whole cell lysates were obtained by gentle lysis using the BugBuster protein extraction reagent (Novagen). Bacterial debris was pelleted, and the supernatant was subjected to metal-affinity chromatography using an Equilibrate His-Bind Column (Novagen). Urea and salt were removed by gel filtration using a PD-10 Sephadex G-25M column (Amersham Biosciences). The TAT protein identity was confirmed by Western blotting.
Determination of TAT-NPM fusion protein uptake and subcellular localization.
The purified TAT-NPM fusion proteins were labeled using the EZ-Label FITC protein Labeling Kit (Pierce) in accordance with manufacturer's instruction. To determine the uptake efficiency of the fusion proteins, 1 x 10 5 HEK293 cells per well were plated in Sca-1-PE antibodies (BD PharMingen) followed by cell sorting using a FACSCalibur (BD Biosciences). Cells were cultured in IMDM medium containing 100 ng/ml of stem cell factor (SCF), 20 ng/ml of interleukin (IL)-6, 10 ng/ml of IL-11 and 50 ng/ml of Flt-3 ligand (Flt-3L) (Peprotech) with or without 10 ng/ml of TNF-α for 30 days.
Clonogenic progenitor assays. WT BM cells or Fancc-/-pre-leukemic cells were incubated with the indicated proteins for 30 min prior to culture in a 35 mm tissue culture dish in 4 ml of semisolid medium containing 3 ml of MethoCult M 3134 (Stem Cell Technologies), the indicated proteins at 30 ug/ml, and the following growth factors: 100 ng/mL SCF, 10 ng/mL IL-3, 100 ng/mL granulocyte colony-stimulating factor (G-CSF), and 4 U/mL erythropoietin (Peprotech). On day 10 after plating, erythroid and myeloid colonies were enumerated. Hematopoietic clonal growth results were expressed as means (of triplicate plates) ± S.D. 
Transduction of TAT-NPM proteins into

Determination of NF-κB nuclear translocation and DNA-binding activity.
Nuclear protein extracts were prepared from BM cells using a Transfactor Extraction kit (BD Biosciences). Nuclear extracts were incubated with DNA specific for the NF-κB consensus sequence, and the DNA binding activity of NF-κB was measured using a Transfactor kit (BD Biosciences).
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Real-time PCR was performed on a ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA) with SYBR green PCR master mix (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Samples were normalized to the level of GAPDH mRNA, and the relative expression levels were determined by the standard curve method. Chromatin immunoprecipitation (ChIP) assays were performed as previously described (17) using either anti-6×His or anti-p65 antibodies (both from Santa Cruz) for immunoprecipitation.
Statistics. Data were analyzed statistically using a two-tail Student's t test or
Kaplan-Meier survival analysis. Statistical significance was presumed when p < 0.05.
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Results
TAT-NPM∆C induces senescence and apoptosis in primary fibroblasts
Because NPM functions to suppress cellular senescence and apoptosis and is essential for development (7, 18), we reasoned that this important molecule may have therapeutic value. We therefore studied NPM transduction by PTD. Since we previously showed that a truncated mutant containing the N-terminal 174 aa (NPM∆C) induced apoptosis in unstressed cells as well as in cells treated with genotoxic agents (19), we generated TAT-fusion proteins containing the full-length NPM, NPM∆N containing the C-terminal 108 aa, and NPM∆C. These fusion proteins were expressed in bacteria and purified ( Fig. 1 ). To examine whether these TAT fusions were biologically active, we determined their effect on the growth of murine embryonic fibroblasts (MEFs) isolated from WT and Fancc-/-mice. We chose Fancc-/-MEFs because they undergo premature senescence under standard fibroblast culture conditions (7). TAT-NPM suppressed senescence in Fancc-/-MEFs, which was consistent with previous report (7); whereas both TAT-NPM∆N and TAT-NPM∆C completely lost this function ( Fig. 2A) . Furthermore, we found that TAT-NPM and TAT-NPM∆C had opposite effect on cell proliferation. That is, TAT-NPM enhanced proliferation while TAT-NPM∆C suppressed cell growth (Fig. 2B ). In addition, TAT-NPM∆C induced apoptosis in WT MEFs and significantly increased apoptotic Fancc-/-cells compared to untreated controls (Fig. 2C) . In contrast, TAT-NPM and TAT-NPM∆N did not have significant effect on the survival of either WT or
Fancc-/-cells (Fig. 2C).
12
The differential effects of TAT-NPM and TAT-NPM∆C on cell survival and proliferation was not due to transduction efficiency, as the uptake of these TAT fusions appeared to be similar between TAT-NPM and TAT-NPM∆C (Fig. 2D) . The intracellular delivery of the TAT-fusions was rapid, as the FITC-labeled fusions could be detected in the treated cells as early as 10 min after incubation (Fig. 2E) . To determine the cellular localization of TAT-NPM fusions, we treated cells with the TAT fusions for 30 min, washed the cells extensively, and incubated them in the absence of the TAT fusions for 60 min before fixation. We found that while TAT-NPM was localized in the nucleolus, the majority of TAT-NPM∆C was localized in nucleoplasm (Fig. 2F) .
TAT-NPM∆C down-regulates anti-apoptotic and pro-inflammatory genes
Because TAT-NPM∆C inhibited cell proliferation and induced apoptosis, we wanted to know if the mutant TAT fusion affected the expression or/and activities of factors involved in cell-cycle control and survival signaling. We first examined the expression and activities of the cell-cycle regulators p53, p21 WAF1 , p16 INK4A , and p19 Arf , known to be negatively regulated by NPM (7, [19] [20] [21] [22] We also examined the expression of the positive cell-cycle regulators including cyclins A, B, D and E, and cyclin-dependent kinases cdc2 (Cdk1), Cdk2, 4 and 6 in MEF cells. We did not observe significant changes in the expression of these molecules in TAT-NPM∆C-treated cells (Fig. 3B) . However, we found significantly reduced levels of cellular inhibitor of apoptosis proteins (cIAP)-1, cIAP-2, Bcl-2, and Bcl-XL in TAT-NPM∆C-treated cells compared with cells treated with TAT-NPM (Fig. 3C) . Surprisingly, the expression of pro-inflammatory cytokines tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, macrophage inflammatory protein (MIP)-2 and cyclooxygenase 2 (Cox-2) was also reduced by TAT-NPM∆C treatment (Fig. 3D ).
TAT-NPM∆C inhibits NF-κB transactivation
Since the expression of the mentioned inflammatory and anti-apoptotic genes is controlled by NF-κB (23) , and since NPM can act to activate NF-κB (24) , this would suggest that TAT-NPM∆C induces apoptosis through a mechanism involving suppression of NF-κB activation. To test this notion, we examined the effect of TAT-NPM∆C on nuclear translocation and DNA-binding activity of NF-κB in normal lymphoblast cells stimulated with TNF-α. Surprisingly, we found that higher level of NF-κB subunit p65 (RelA) was detected in TAT-NPM∆C-treated cells than those treated with TAT-NPM or BSA (Fig. 4A) . Consistent with this, significant increase in
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For personal use only. on November 12, 2017. by guest www.bloodjournal.org From DNA binding by p65 was observed in TAT-NPM∆C-treated cells, as compared to cells treated with TAT-NPM or BSA (Fig. 4B) . It is noteworthy that TAT-NPM also enhanced DNA-binding activity of p65, which is consistent with previous observation that NPM activates NF-κB (24) . Furthermore, TAT-NPM∆C greatly prolonged the time of TNF-α-induced NF-κB accumulation in nuclei (Fig. 4C) .
We next examined the effect of TAT-NPM∆C on NF-κB transactivation by transient reporter gene assays in HEK293T cells using a luciferase construct with an NF-κB-driven promoter. Cells transduced with TAT-NPM showed enhanced NF-κB luciferase reporter activity induced by TNF-α (Fig. 4D) . In contrast, TAT-NPM∆C inhibited NF-κB activation induced by TNF-α treatment. Interestingly, the basal activity of the NF-κB luciferase reporter was also significantly reduced in TAT-NPM∆C-treated cells (Fig. 4D) . Together, these results demonstrate that TAT-NPM∆C acts as a negative regulator of the NF-κB pathway. (16) . This inflammationassociated leukemogenic model therefore provided us a unique opportunity to test whether TAT-NPM∆C exerted an inhibitory effect on leukemia development in vivo.
Intracellular delivery of TAT-NPM∆C induces apoptosis in
First, we examined proliferation and repopulating capacity of TAT-NPM∆C-treated Fancc-/-pre-leukemic stem cells using clonogenic and bone marrow transplantation assays. We found that TAT-NPM∆C transduction significantly suppressed clonogenic proliferation (Fig. 5A, S1A ) and hematopoietic repopulating ability (Fig.   5B , S1B) of the Fancc-/-pre-leukemic cells compared to BSA-treated cells.
Interestingly, we did not observed further increase in colony-forming and repopulating ability of Fancc-/-pre-leukemic cells treated with TAT-NPM compared to BSA-treated cells (Fig. 5, S1 ). However, we observed a significant increase in apoptosis in colony-forming cells and bone marrow repopulating cells of the TAT-NPM∆C-treated Fancc-/-pre-leukemic stem cells (Fig. 5C ).
While the data presented above demonstrate that four-week treatment of the recipient mice with TAT-NPM∆C reduced hematopoietic repopulating ability of the Fancc-/-pre-leukemic stem cells, it would be of importance to know whether the TAT-fusion was effective in inhibiting leukemia development. We therefore 
in BM cells from the recipient mice at various time points after a single injection. It appeared that TAT-NPM and TAT-NPM∆C were delivered at a similar rate and could be detected in BM cells of the recipient mice for up to 12 hrs after injection (Fig. S2 ).
Recipients injected with BSA developed acute myeloid leukemia within 150 days (Fig. 6A) , consistent with previous report (16) . The time required for leukemia to develop in recipients treated with TAT-NPM was indistinguishable from that of BSAtreated mice, regardless of the duration of the treatment. However, the occurrence of leukemia was significantly delayed in recipients injected with TAT-NPM∆C fusion, with long-term (12 weeks) treatment showing the better effect than the short-term (4 weeks) treatment (Fig. 6A) . Furthermore, TAT-NPM∆C treatment clearly reduced cell proliferation, as evaluated by BrdU incorporation in the leukemic cells (Fig. 6B) and Ki-67 antigen staining in the spleen and liver of the recipient mice (Fig. 6C) .
TUNEL assay showed increased apoptosis in the bone marrow of the recipient mice treated with TAT-NPM∆C compared with BSA-or TAT-NPM-treated recipients (Fig.   6D ). Collectively, these results demonstrate that TAT-NPM∆C induces apoptosis and proliferative suppression of Fancc-/-leukemic cells and delays leukemia development.
TAT-NPM∆C forms complexes with endogenous NPM and p65 at promoters of anti-apoptotic and inflammatory genes and abrogates their transactivation by NF-κB in pre-leukemic cells
To further investigate the mechanism by which TAT-NPM∆C inhibited NF-κB activation, we first examined the relationship of TAT-NPM∆C and endogenous NPM (Fig. 7A) . This might explain our finding that no further increase in colony-forming and repopulating ability were observed in Fancc-/-preleukemic cells treated with TAT-NPM (Fig. 6A,B) , as the level of the endogenous NPM with the same functionality as TAT-NPM was already high enough. Shortly (30 min) after treatment, both TAT-NPM and TAT-NPM∆C associated with endogenous NPM in nuclei of Fancc-/-pre-leukemic cells (Fig. 7B) . This was not surprising because NPM∆C retains the N-terminal oligomerization domain (25) . We further confirmed the observed interaction between the NPM fusions and endogenous NPM using a normal lymphoblast cell line that expressed FLAG-NPM or FLAG-NPM∆C (Fig. 7C) . It has been reported that NPM interacts with p19
Arf and regulates the biological function of p19 Arf (26, 27) . We thus determined p19ARF protein levels and interaction between TAT-NPM and p19 Arf or between TAT-NPM∆C and p19 Arf in
Fancc-/-pre-leukemic cells. Our results show that treatment of the Fancc-/-preleukemic cells with or without the TAT-NPM fusions did not affect p19 Arf protein levels, and that only the full-length TAT-NPM interacted with p19 Arf (Fig. 7D) .
To study the functional consequence of the interaction between TAT-NPM∆C and endogenous NPM in the context of NF-κB inhibition, we first asked whether TAT-NPM∆C inhibited NF-κB in vivo by determining NF-κB activity in the treated recipient mice. As shown in Fig 7E, (Fig. 7F) .
Next, we utilized ChIP assay to determine whether in vivo association of TAT-NPM∆C with endogenous NPM affected the binding of NF-κB to the promoters of IL-6 and MIP-2 genes. After 30 min of TNF-α stimulation, the association of TAT-NPM∆C and p65 with the kB-responsive elements at the IL-6 promoter was increased in TAT-NPM∆C-treated Fancc-/-pre-leukemic cells compared to BSA or TAT-NPM-treated cells (Fig. 7G) . Similarly, the association TAT-NPM∆C and p65 with the MIP-2 promoter was also increased in TAT-NPM∆C-treated cells.
Importantly, both 6×His and p65 ChIPs showed prolonged residence of TAT-NPM∆C and p65 at NF-κB-responsive promoters of the IL-6 and MIP-2 genes in TAT-NPM∆C-treated Fancc-/-pre-leukemic cells (Fig. 7G) . This may explain the prolonged TNF-α-induced NF-κB accumulation in nuclei of TAT-NPM∆C-treated cells (Fig. 4C) . Consistent with its inhibitory effect on NF-κB activation, TAT-NPM∆C greatly down-regulated expression of pro-inflammatory and anti-apoptotic genes in Fancc-/-pre-leukemic cells, such as IL-6, COX2, Bcl-XL, and cIAP-1 known to be the targets of NF-κB (Fig. 7H) . Therefore, TAT-NPM∆C appears to inhibit NF-κB activation by binding to p65-associated endogenous NPM and thus converting NF-κB to a transcriptionally inactive or repressive state.
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Discussion
Given that NPM is frequently up-regulated in actively proliferating cells and human cancers (1) (2) (3) (4) (5) (6) , it is of great interest to investigate the therapeutic value by targeting the overexpressed NPM in tumor cells. In this paper, we present a novel protein therapy targeting the overexpressed NPM in inflammation-associated leukemia. We TAT-NPM∆C appears to be very potent in repressing NF-κB transactivation of numerous inflammatory and anti-apoptotic genes, which may explain our observations that TAT-NPM∆C could effectively act to induce apoptosis in leukemic cells and delay the development of inflammation-associated leukemia in mice. NPM has been identified as an NF-κB co-activator (24) . The results of the present study
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For personal use only. on November 12, 2017. by guest www.bloodjournal.org From clearly demonstrate TAT-NPM∆C-mediated repression of the expression of inflammatory and anti-apoptotic genes that is dependent on NF-κB. The results also reveal the underlying mechanism of inhibition. That is, TAT-NPM∆C forms a tertiary complex with the endogenous NPM and NF-κB, thus converting NF-κB to a transcriptionally inactive state that becomes trapped at κB element-containing promoters. This notion is supported by the finding that the inhibition of NF-κB transactivation by TAT-NPM∆C is accompanied by a paradoxical increase in the nuclear accumulation and the DNA-binding activity of NF-κB. This mechanism of action is in contrast with that of the classic NF-κB inhibitors, which act to prevent NF-κB nuclear translocation by inhibiting the phosphorylation and degradation of IκBα (28, 29) . Persistent NF-κB activation is commonly observed in inflammatory diseases and malignancies (30) and overexpression of NPM is often found in human cancers (1) (2) (3) (4) (5) (6) . In this context, utilization of the TAT-delivered NPM∆C to not only convert NF-κB to inactive state but also sequester the overexpressed endogenous NPM to biologically non-functional protein complexes may prove to be therapeutically attractive.
In addition to inhibiting NF-κB, TAT-NPM∆C appears to be able to activate p53 in cultured primary cells. The precise mechanism by which TAT-NPM∆C induces the activation of endogenous p53 in the steady state remains to be further elucidated; however, our results indicate that treatment of pre-senescent cells with TAT-NPM∆C strongly enhanced phosphorylation of p53 at the Ser15 residue and subsequently induced p53 target p21 WAF1/CIP1 (Fig. 4) . Phosphorylation at the Ser15
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For personal use only. on November 12, 2017. by guest www.bloodjournal.org From residue of p53 is critical for p53-dependent transactivation (31) . The ability of TAT-NPM∆C to augment p53 activity can explain, at least in part, its ability to induce apoptosis and to accelerate senescence in unstressed cells (Fig. 2) . Loss of p53 functions has been implicated in more than 50% of human cancers due to inactivating mutations (32) . Therefore, reactivation of p53 functions or inactivation of p53 negative regulators has long been considered as an effective therapy for cancers. The data provided here reveal that the TAT-delivered NPM∆C causes a significant increase of the active form of p53 and thus suggest that TAT-NPM∆C might be able to reactivate the p53-mediated apoptotic pathway in tumor cells. In this context, TAT-NPM∆C could be used as a novel therapeutic agent in combination with DNA damage drugs for cancer prevention and treatments.
The dual effect of TAT-NPM∆C as a NF-κB inhibitor and a p53 activator raises an important question of whether the effects of TAT-NPM∆C on NF-κB inhibition and p53 activation are interrelated. The observation that TAT-NPM∆C exerted its negative effect on NF-κB by forming an inactive complex with the endogenous NPM and NF-κB excludes the possibility that would place TAT-NPM∆C-induced p53 activation upstream of NF-κB inhibition, as TAT-NPM∆C appears to exert its negative effect directly on NF-κB. Mechanisms of mutual negative regulation of NF-κB and p53 have been reported (33) . Recently, it has been shown that inhibition of NF-κB by small molecules reactivates p53 in renal cell carcinoma (34) , suggesting that there are unidentified regulatory factors that provide interactions between NF-κB and p53 signaling pathway. Another possibility is that
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TAT-NPM∆C could act on p53 in parallel with NF-κB inhibition. The exact mechanism remains to be determined.
In conclusion, we have demonstrated the efficiency and biological activity of intracellular delivery of a mutant NPM peptide using TAT PTD, thereby providing a novel protein therapy targeting the overexpressed NPM in inflammation-associated leukemia. TAT-NPM∆C may also be applicable for other tumors and disease conditions that require NF-κB signaling for survival.
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